Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Pembrolizumab in Sarcoma: NCT07410676 Clinical Landscape Report 2026
18 September 2026
NCT07410676 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD19-CAR novel oncolytic vaccinia virus(The Second Affiliated Hospital Zhejiang University) in Indolent B-Cell Non-Hodgkin Lymphoma: NCT07398963 Clinical Landscape Report 2026
18 September 2026
NCT07398963 clinical landscape for Indolent B-Cell Non-Hodgkin Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Lisaftoclax in Diffuse Large B-Cell Lymphoma: NCT07398638 Clinical Landscape Report 2026
18 September 2026
NCT07398638 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Renal Cell Carcinoma: NCT07401875 Clinical Landscape Report 2026
18 September 2026
NCT07401875 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Trastuzumab in Residual Neoplasm: NCT07407920 Clinical Landscape Report 2026
18 September 2026
NCT07407920 clinical landscape for Residual Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Ovarian Cancer: NCT07407452 Clinical Landscape Report 2026
18 September 2026
NCT07407452 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Polatuzumab Vedotin-Piiq in Diffuse Large B-Cell Lymphoma: NCT07415980 Clinical Landscape Report 2026
18 September 2026
NCT07415980 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fianlimab/Cemiplimab in Urothelial Carcinoma of the Urinary Bladder: NCT07414992 Clinical Landscape Report 2026
18 September 2026
NCT07414992 clinical landscape for Urothelial Carcinoma of the Urinary Bladder: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Carboplatin in Triple Negative Breast Cancer: NCT07413601 Clinical Landscape Report 2026
18 September 2026
NCT07413601 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Varnimcabtagene autoleucel in Mantle-Cell Lymphoma: NCT07412405 Clinical Landscape Report 2026
18 September 2026
NCT07412405 clinical landscape for Mantle-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dutasteride in Non-Muscle Invasive Bladder Neoplasms: NCT07420517 Clinical Landscape Report 2026
18 September 2026
NCT07420517 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
ITC-6146RO in Metastatic Solid Tumor: NCT07423117 Clinical Landscape Report 2026
18 September 2026
NCT07423117 clinical landscape for Metastatic Solid Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.